Bladder Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Urothelial Cancer (248)

›

HER-2 amplification	Bladder Cancer	HER-2 amplification	Bladder Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials AACR 2023 - 2 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : C3 AACR 2023 - 2wk	fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials AACR 2023 - 2 weeks fam-trastuzumab deruxtecan-nxki Sensitive : C3 AACR 2023 - 2 weeks - (New C3)
FGFR3 overexpression	Bladder Cancer	FGFR3 overexpression	Bladder Cancer	AMB302 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) AMB302 Sensitive : D AACR 2023 - 2wk	AMB302 Sensitive: D – Preclinical AACR 2023 - 2 weeks AMB302 Sensitive : D AACR 2023 - 2 weeks - (New D)
FGFR3-TACC3 fusion	Bladder Cancer	FGFR3-TACC3 fusion	Bladder Cancer	AMB302 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) AMB302 Sensitive : D AACR 2023 - 2wk	AMB302 Sensitive: D – Preclinical AACR 2023 - 2 weeks AMB302 Sensitive : D AACR 2023 - 2 weeks - (New D)
KRAS G12C	Bladder Cancer	KRAS G12C	Bladder Cancer	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 2wk	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 2 weeks adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 2 weeks - (New D)
KRAS G12C	Bladder Cancer	KRAS G12C	Bladder Cancer	sotorasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) sotorasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 2wk	sotorasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 2 weeks sotorasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 2 weeks - (New D)
GSDMB expression	Bladder Cancer	GSDMB expression	Bladder Cancer	anlotinib Sensitive: D – Preclinical Pharmgenomics Pers Med - 2 weeks (New D) anlotinib Sensitive : D Pharmgenomics Pers Med - 2wk	anlotinib Sensitive: D – Preclinical Pharmgenomics Pers Med - 2 weeks anlotinib Sensitive : D Pharmgenomics Pers Med - 2 weeks - (New D)
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	nadofaragene firadenovec Sensitive: A1 - Approval nadofaragene firadenovec Sensitive : A1	nadofaragene firadenovec Sensitive: A1 - Approval nadofaragene firadenovec Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	EP Sensitive: A2 - Guideline EP Sensitive : A2	EP Sensitive: A2 - Guideline EP Sensitive : A2
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive : A2	cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	enfortumab vedotin Sensitive: A2 - Guideline enfortumab vedotin Sensitive : A2	enfortumab vedotin Sensitive: A2 - Guideline enfortumab vedotin Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	paclitaxel + gemcitabine Sensitive: A2 - Guideline paclitaxel + gemcitabine Sensitive : A2	paclitaxel + gemcitabine Sensitive: A2 - Guideline paclitaxel + gemcitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	avelumab Sensitive: A2 - Guideline avelumab Sensitive : A2	avelumab Sensitive: A2 - Guideline avelumab Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	sacituzumab govitecan-hziy Sensitive: A2 - Guideline sacituzumab govitecan-hziy Sensitive : A2	sacituzumab govitecan-hziy Sensitive: A2 - Guideline sacituzumab govitecan-hziy Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	ddMVAC Sensitive: A2 - Guideline ddMVAC Sensitive : A2	ddMVAC Sensitive: A2 - Guideline ddMVAC Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	inbakicept Sensitive: B - Late Trials inbakicept Sensitive : B	inbakicept Sensitive: B - Late Trials inbakicept Sensitive : B
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
HLA-A*03	Bladder Cancer	HLA-A*03	Bladder Cancer	CTLA4 inhibitor Resistant: B - Late Trials CTLA4 inhibitor Resistant : B	CTLA4 inhibitor Resistant: B - Late Trials CTLA4 inhibitor Resistant : B
HLA-A*03	Bladder Cancer	HLA-A*03	Bladder Cancer	PD-L1 inhibitor Resistant: B - Late Trials PD-L1 inhibitor Resistant : B	PD-L1 inhibitor Resistant: B - Late Trials PD-L1 inhibitor Resistant : B
HLA-A*03	Bladder Cancer	HLA-A*03	Bladder Cancer	PD1 inhibitor Resistant: B - Late Trials PD1 inhibitor Resistant : B	PD1 inhibitor Resistant: B - Late Trials PD1 inhibitor Resistant : B
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	AU-011 Sensitive: B - Late Trials AU-011 Sensitive : B	AU-011 Sensitive: B - Late Trials AU-011 Sensitive : B

Bladder Cancer

Associations(143)

Associations
(143)